Rigor Reviewed

Rigor-Reviewed Manuscript

Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.

Name: Αlpha¹ Rigor Record — Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.
Item: Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.
Rating: 100
Author: Αlpha¹

Borowsky B, Ramos H, Caputo A, Hartmann A, Faller T, Peters T, Sui Y, Liu F, Meadowcroft M, David OJ, Laisney M, Kinhikar A, Marder KS, Tabrizi SJ, Landwehrmeyer GB, Leavitt BR

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.5★ (Adequate), 0 critical, 0 high issues for “Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 14 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted phase 2b randomized, double-blind, placebo-controlled trial with rigorous design, clear ethical approvals, and transparent reporting. The main weaknesses are minor reporting gaps: lack of explicit reporting guideline statement, missing confidence intervals for the primary endpoint, and unspecified NHP housing conditions.

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence was present. The statistics verification component found no recomputable tests (total=0), so statistical correctness was not independently verified; the citation component found no retracted or unresolved references.

7 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction extensively cites prior research on HD, HTT lowering strategies, and branaplam's mechanism and preclinical effects. It acknowledges both the promise and the risks (e.g., neurotoxicity in dogs) and explains how the study design addresses these. The rationale for the trial is logically derived from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on HTT lowering, branaplam's mechanism, and preclinical safety data, and clearly links this to the study rationale.

Evidence

paraphrase[Introduction, paragraphs 1-4]

“Lowering the expression of total or mutant HTT in the brain is associated with a corresponding decrease in HTT levels in the cerebrospinal fluid (CSF), and a reduction of up to 40% in CSF mHTT has been shown to be safe and well tolerated in humans.”

paraphrase[Introduction, paragraph 5]

“The broad distribution of branaplam throughout the brain and periphery... combined with the ability to monitor for potential safety risks, provided a strong foundation for investigating the benefit–risk ratio of branaplam in people with HD.”

paraphrase[Discussion, paragraph 1]

“To mitigate the potential risk of neurotoxicity, as identified by preclinical animal studies in dogs and preliminary results in NHPs, we developed an innovative protocol including a staggered cohort approach along with multimodal monitoring for neurotoxicity.”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior work on HTT lowering, branaplam's mechanism, and preclinical safety data, and clearly links this to the study rationale.

Evidence

paraphrase[Introduction, paragraphs 1-4]

direct quote[Introduction, last paragraph]

“This study aimed to identify a safe and well-tolerated oral dose of branaplam administered weekly that would lower CSF mHTT levels sufficiently to expect a clinical benefit.”